Altimmune Inc stock is traded at $1.93, with a volume of 2,939,815. It is down -0.52% in the last 24 hours and down -24.61% over the past month. Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Previous Close:
$1.94
Open:
$1.95
24h Volume:
2,939,815
Relative Volume:
0.89
Market Cap:
$375.42M
Revenue:
$36,000
Net Income/Loss:
-$91.08M
P/E Ratio:
-
EPS:
-$0.9376
Net Cash Flow:
-$71.67M
1W Performance:
-2.03%
1M Performance:
-24.61%
6M Performance:
-37.34%
1Y Performance:
-54.37%
1-Day Range:
$1.90$1.99
1-Week Range:
$1.90$2.21
52-Week Range:
$1.90$6.44
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune IncSector
HealthcareIndustry
BiotechnologyPhone
(240) 654-1450Address
910 CLOPPER ROAD, GAITHERSBURG, MD, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS